

China Development Forum 2024
The Continuous Development of China
Symposium on Promoting the ‘Big Health’
(Keynote Speech Two)

The China Development Forum (CDF) 2024, hosted by the Development Research Centre of the State Council (DRC) and organized by the China Development Research Foundation (CDRF), was held at Diaoyutai State Guesthouse in Beijing on 24-25 March 2024. The Symposium on Promoting the ‘Big Health’ was held on the afternoon of 24 March, chaired by LI Jianwei, Director-General of the Research Department of Social and Cultural Development, DRC. In the Keynote Speech Two session, the speaker was BI Jingquan, Deputy Director of the Committee on Economic Affairs, CPPCC, and Chairman of CCIEE.

In his keynote speech titled “Striving to Improve the Ecological Environment for the Development of the Innovative Drug Industry”, BI Jingquan stated that China’s innovative drug industry is taking shape. Since the 18th National Congress of the Communist Party of China, the Chinese biopharmaceutical industry has achieved leapfrog development, transitioning from a focus on generic drugs to a combination of innovative and generic drugs. China has many favorable conditions for developing the innovative drug industry, such as a huge potential market for biopharmaceuticals, abundant and high-quality labor resources, rich

clinical research resources, and a review and approval system that is largely aligned with international standards. Furthermore, the Chinese government places high importance on the development of innovative drugs. The speed at which innovative drugs are included in the national medical insurance reimbursement list has accelerated, and the barriers to the entry of drugs into hospitals are gradually being eliminated.

BI Jingquan said that to further accelerate the development of the innovative drug industry, China needs to continue efforts in the following eight points:

1. The understanding of the clinical value of innovative drugs shall be deepened. Innovative drugs have three characteristics: they are patented, meet clinical needs, and have market promotion value. Understanding the essential characteristics and development patterns of innovative drugs can help us correctly recognize their clinical value, which is significant for encouraging and supporting the development of the innovative drug industry.

2. Basic research in life sciences shall be strengthened. It is imperative to further tilt national support for basic research towards life sciences; improve policies to encourage social capital investment in basic research in life sciences; encourage individuals and companies to establish funds to support basic scientific research, etc.

3. The pricing mechanism and medical insurance payment methods for innovative drugs shall be reformed. It is imperative to vigorously develop commercial medical insurance, establish a multi-level medical security system to open new payment channels for innovative drugs; disclose medical data for various diseases; expedite the formulation of commercial medical insurance laws; promote the reform of the

commercial medical insurance system, etc.

4. A basic medical security system for the elderly shall be established. It is suggested to allocate some funds specifically for basic medical and care services for people over 65 years old, entrusted to social institutions. At the same time, encourage insurance companies to offer supplementary commercial insurance for the elderly, catering to the multi-level medical needs of certain groups, such as seeing specialists, taking quality medications, and staying in private rooms.

5. The reform of the compensation mechanism for public hospitals shall be deepened. It is imperative to eliminate various unreasonable restrictions on the entry of innovative drugs into hospitals. Under the principle of total control and structural adjustment, and without increasing the overall burden of medical expenses on society, rationalization of medical service prices shall be achieved.

6. The drug review and approval system shall be further improved. It is imperative to strengthen the publicity of the clinical prices of innovative drugs and disclose the technical approval conclusions and data on the effectiveness and safety of innovative drugs when they go on the market. The construction of the drug reviewer team shall be strengthened.

7. Various policies to protect intellectual property rights shall be effectively implemented. It is imperative to provide patent term compensation for all innovative drugs that go on the market during the patent period; effectively implement the various provisions of the early resolution mechanism for pharmaceutical patent disputes; expedite the establishment of a data protection system, etc.

8. International cooperation in the research and development and application fields of innovative drugs shall be strengthened. It is

imperative to encourage international exchanges among the scientific community, medical community, and biopharmaceutical companies, and promote the global flow of production factors.

(China Development Press Written by: Zhao Haijuan Reviewed by: Cui Keliang)

--Background Information--

Under the mandate 'Engaging with the world for common prosperity', China Development Forum (CDF) serves as an important platform for Chinese government to carry out candid exchanges and discussions with leaders of global businesses and international organizations as well as foreign and Chinese scholars. Initiated in 2000, CDF has made remarkable contributions for the policy exchange and international collaborations between China and the world.

--Media Contact--

CDRF

Guo Silu 18666028168/64255855-8014

Shi Yafan 13810361966/64255855-8223

Xia Tian 18801375838/64255855-8086

Shi Wanjing 18801090391/64255855-8090

Qiu Kaixian 18301078627/64255855-8103



中国发展研究基金会
China Development Research
Foundation

中国北京东城区安定门外大街138号
皇城国际中心A座15层

Floor15, Tower a, Imperial International Center, No.138
Andingmen Wai Avenue, Dongcheng District, Beijing, 100011, China

邮编: 100011
电话: 86-10-64255855
传真: 86-10-64255855-8100
网址: www.cdrf.org.cn
电邮: cdrf@cdrf.org.cn

Tel: 86-10-64255855
Fax: 86-10-64255855-8100
Website: www.cdrf.org.cn
E-mail: cdrf@cdrf.org.cn